# Bayer brings new treatment option for chronic heart failure patients in India 

27 September 2022 | News

In India there are between 8-10 million people with heart failure (HF), making it one of the largest HF populations in the world


Bayer has announced the launch of vericiguat (Verquvo), a soluble guanylate cyclase (sGC) stimulator, in India. Vericiguat is indicated, along with guideline-based medical therapy, in adults with symptomatic chronic heart failure with reduced ejection fraction (less than 45\%), following a recent event of worsening heart failure which required hospitalization or outpatient intravenous (IV) diuretics.

Vericiguat works on a pathway not currently targeted by existing heart failure treatments and can reduce the risk of cardiovascular death and heart failure hospitalization in such patients.

Manoj Saxena, Managing Director, Bayer Zydus Pharma, says, "Despite therapy, chronic heart failure patients can experience disease progression that disrupts their lives and leads to worsening heart failure events, where hospitalization or initiation of intravenous diuretics are needed. After an event of worsening heart failure, more than $50 \%$ of patients may require re-hospitalization within 30 days. The in-hospital mortality rate in India is also high and registry data suggest that it ranges between $10-30.8 \%$ as compared with $4-7 \%$ in Western countries. Verquvo can help patients stay out of the hospital and improve the chances of survival in such patients."

Vericiguat is currently approved for use in 35 countries including the United States, European Union countries, the United Kingdom, Japan and Singapore. Vericiguat is the only treatment that has been recommended following a worsening heart failure event, on top of foundational heart failure therapies in major international guidelines

Verquvo will be made available to address the needs of HF patients in India at an India-specific price, almost at the same time as HF patients in around the world.

